PE20001467A1 - Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina - Google Patents

Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina

Info

Publication number
PE20001467A1
PE20001467A1 PE2000000125A PE0001252000A PE20001467A1 PE 20001467 A1 PE20001467 A1 PE 20001467A1 PE 2000000125 A PE2000000125 A PE 2000000125A PE 0001252000 A PE0001252000 A PE 0001252000A PE 20001467 A1 PE20001467 A1 PE 20001467A1
Authority
PE
Peru
Prior art keywords
alkyl
phenylpyridine
derivatives
alcoxy
trifluoromethyl
Prior art date
Application number
PE2000000125A
Other languages
English (en)
Spanish (es)
Inventor
Quirico Branca
Michael Bos
Guido Galley
Heinz Stadler
Torsten Hoffmann
Walter Hunkeler
Patrick Schnider
Thierry Godel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20001467A1 publication Critical patent/PE20001467A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
PE2000000125A 1999-02-24 2000-02-18 Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina PE20001467A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99103504 1999-02-24
EP99123689 1999-11-29

Publications (1)

Publication Number Publication Date
PE20001467A1 true PE20001467A1 (es) 2000-12-20

Family

ID=26152908

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000125A PE20001467A1 (es) 1999-02-24 2000-02-18 Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina

Country Status (54)

Country Link
US (2) US6297375B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP1035115B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP3399900B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100384904B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1142144C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (2) AR029614A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (2) ATE277905T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU767048B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE2015C057I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG64554B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0000908B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2299139C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (3) CY1111317T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ300596B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (3) DE60045564D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK1394150T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA003673B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EG (1) EG23817A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (3) ES2226622T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (2) FR2790473B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB2347422A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GE (1) GEP20022676B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GT (1) GT200000017A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (2) HRP20000097B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU227629B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL134654A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IS (1) IS2116B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT (1) IT1320763B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JO (1) JO2294B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LTC1035115I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU92745I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA26722A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ME (1) ME00593B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (2) MY123648A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300758I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO315554B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ502948A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
OA (1) OA11680A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PA (1) PA8491101A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20001467A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL217311B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (2) PT1035115E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (3) RS50194B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SE (1) SE1035115T5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG91856A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI1035115T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (2) SK287911B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SV (1) SV2002000024A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TN (1) TNSN00032A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (1) TR200000520A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI288746B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA71547C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UY (1) UY32314A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200000894B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058640A2 (en) * 1998-05-11 1999-11-18 Philadelphia Health And Education Corporation Mct-1, a human oncogene
RU2238264C2 (ru) * 1999-02-24 2004-10-20 Đ€.Đ„ĐŸŃ„Ń„ĐŒĐ°ĐœĐœ-Ля Đ ĐŸŃˆ Аг ĐŸŃ€ĐŸĐžĐ·ĐČĐŸĐŽĐœŃ‹Đ” Đ±Đ”ĐœĐ·ĐŸĐ»Đ° ОлО ĐżĐžŃ€ĐžĐŽĐžĐœĐ° Đž Ń„Đ°Ń€ĐŒĐ°Ń†Đ”ĐČтОчДсĐșая ĐșĐŸĐŒĐżĐŸĐ·ĐžŃ†ĐžŃ ĐœĐ° ох ĐŸŃĐœĐŸĐČĐ”
US6291465B1 (en) * 1999-03-09 2001-09-18 Hoffmann-La Roche Inc. Biphenyl derivatives
ATE253561T1 (de) * 1999-11-29 2003-11-15 Hoffmann La Roche 2-(3,5-bis-trifluoromethyl-phenyl)-n-methyl-n-( - morpholin-4-yl-4-o-tolyl-pyridin-3-yl)- isobutyramid
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
JP3938651B2 (ja) * 2000-04-13 2007-06-27 ă‚»ăƒłăƒˆăƒ©ăƒ«çĄć­æ ȘćŒäŒšç€Ÿ ć…‰ć­ŠæŽ»æ€§Î±âˆ’ăƒĄăƒăƒ«âˆ’ăƒ“ă‚čâˆ’ïŒ“ă€ïŒ•âˆ’ïŒˆăƒˆăƒȘăƒ•ăƒ«ă‚Șăƒ­ăƒĄăƒăƒ«ïŒ‰ăƒ™ăƒłă‚žăƒ«ă‚ąăƒŸăƒłăźèŁœé€ æ–čæł•
AU7061901A (en) * 2000-07-14 2002-01-30 Hoffmann La Roche N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
KR100602299B1 (ko) * 2000-12-14 2006-07-14 에프. 혾프만-띌 ëĄœìŠˆ 아êȌ 자가 유화성 지질 맀튞늭슀
US6531597B2 (en) 2001-02-13 2003-03-11 Hoffmann-La Roche Inc. Process for preparation of 2-phenyl acetic acid derivatives
US7112593B2 (en) 2001-03-27 2006-09-26 Eisai Co., Ltd. N-aryl-substituted cyclic amine derivative and medicine containing the same as active ingredient
CA2444395C (en) * 2001-04-23 2010-12-21 F. Hoffmann-La Roche Ag Use of nk-1 receptor antagonists against benign prostatic hyperplasia
ATE491474T1 (de) * 2001-06-07 2011-01-15 Sang Christine Dr Behandlung von neuropathischen schmerzen mittels eines n-methyl-d-aspartate (nmda)-rezeptor- antagonists
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
MXPA04002220A (es) * 2001-09-10 2004-06-07 Hoffmann La Roche Formulaciones tixotropicas oleosas.
US7390813B1 (en) 2001-12-21 2008-06-24 Xenon Pharmaceuticals Inc. Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
MXPA05003054A (es) 2002-09-20 2005-05-27 Pfizer Prod Inc Ligandos de amida y sulfonamida para el receptor de estrogenos.
US8729107B2 (en) * 2002-12-06 2014-05-20 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
JP4903385B2 (ja) 2002-12-06 2012-03-28 ăƒ‘ăƒŒăƒ‡ăƒ„ăƒŒăƒ»ăƒȘă‚”ăƒŒăƒăƒ»ăƒ•ă‚Ąă‚Šăƒłăƒ‡ăƒŒă‚·ăƒ§ăƒł æć‚·ă—ăŸć“șäčłéĄžç„žç”Œç”„çč”ă‚’æČ»ç™‚ă™ă‚‹ăŸă‚ăźăƒ”ăƒȘゾン類
EP1592428B1 (en) * 2003-01-31 2007-07-11 F. Hoffmann-La Roche AG New crystalline modification of 2-(3,5-bis-trifluoromethyl-phenyl)-n- 6-(1,1-dioxo-1lamda-6 -thiomorpholin-4-yl)-4(4-fluoro-2-methyl-phenyl)-pyridin-3-yl -n-methyl-isobutyramide
AU2004253267B2 (en) * 2003-07-03 2008-12-04 F. Hoffmann-La Roche Ag Dual NK1/NK3 antagonists for treating schizophrenia
US7288658B2 (en) 2003-07-15 2007-10-30 Hoffmann-La Roche Inc. Process for preparation of pyridine derivatives
ES2375134T3 (es) 2003-07-30 2012-02-27 Xenon Pharmaceuticals Inc. Derivados de piperazina y su uso como agentes terapéuticos.
CA2572645C (en) 2004-07-06 2011-01-18 F. Hoffmann-La Roche Ag Process for preparing carboxamide derivatives used as intermediates in the synthesis of nk-1 receptor antagonists
KR100881240B1 (ko) * 2004-07-06 2009-02-05 에프. 혾프만-띌 ëĄœìŠˆ 아êȌ ïŒźïœ‹-1 수용ìČŽ Ꞟ항제의 합성에 있얎서 쀑간ìČŽëĄœì„œì‚Źìš©ë˜ëŠ” ìčŽë„Žëł”ìŠ€ì•„ëŻžë“œ í”ŒëŠŹë”˜ 유도ìČŽì˜ ì œìĄ° ë°©ëȕ
BRPI0418939A (pt) * 2004-07-06 2008-04-08 Xenon Pharmaceuticals Inc derivados de nicotinamida e sua utilização como agentes terapĂȘuticos
US20060030556A1 (en) * 2004-08-04 2006-02-09 Solvay Pharmaceuticals B.V. Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation, including testosterone deficiency
WO2006013205A1 (en) * 2004-08-04 2006-02-09 Solvay Pharmaceuticals B.V. Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
JP5149009B2 (ja) 2004-09-20 2013-02-20 ă‚ŒăƒŽăƒłăƒ»ăƒ•ă‚ĄăƒŒăƒžă‚·ăƒ„ăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚șăƒ»ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ヒトă‚čăƒ†ă‚ąăƒ­ă‚€ăƒ«âˆ’ïŒŁïœïŒĄăƒ‡ă‚”ăƒăƒ„ăƒ©ăƒŒă‚Œă‚’é˜»ćźłă™ă‚‹ăŸă‚ăźăƒ”ăƒȘダゾンèȘ˜ć°Žäœ“
CA2580857A1 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
MX2007003321A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
WO2006034441A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
BRPI0515505A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados heterocÏclicos e sua utilização como inibidores da estearoil-coa desaturase
EP2289510A1 (en) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
US7569725B2 (en) * 2004-10-21 2009-08-04 Britsol-Myers Squibb Company Anthranilic acid derivatives as inhibitors of 17ÎČ-hydroxysteroid dehydrogenase 3
WO2006060174A1 (en) * 2004-11-15 2006-06-08 Honeywell International Inc. Isocyanate-based polymer foams with nano-scale materials
JP4767973B2 (ja) * 2005-02-22 2011-09-07 ă‚šăƒ•ïŒŽăƒ›ăƒ•ăƒžăƒłâˆ’ăƒ© ăƒ­ă‚·ăƒ„ ă‚ąăƒŒă‚ČăƒŒ ïŒźïœ‹ïŒ‘ă‚ąăƒłă‚żă‚Žăƒ‹ă‚čト
CN101128428A (zh) * 2005-02-24 2008-02-20 è©čæŁźèŻäžšæœ‰é™ć…Źćž 䜜äžșé’ŸçŠ»ć­é€šé“æ‰“ćŒ€ć‰‚çš„æ–°çš„ćĄć•¶èĄç”Ÿç‰©
NZ560232A (en) 2005-02-25 2010-11-26 Hoffmann La Roche Tablets with improved drug substance dispersibility
EP1863767B1 (en) * 2005-03-23 2009-03-11 F. Hoffmann-Roche AG Metabolites for nk-i antagonists for emesis
US8541457B2 (en) 2005-06-03 2013-09-24 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
AU2006279810B2 (en) * 2005-08-11 2011-10-27 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
KR101292348B1 (ko) 2005-09-09 2013-09-09 넀넎 쎄띌퓚틱슀 멬믾티드 í”ŒëŠŹë”˜ 유도ìČŽ 및 귞의 ì •ì‹ ëł‘ì  임애의 ìč˜ëŁŒì— 있얎서의용도
ES2335922T3 (es) * 2005-09-23 2010-04-06 F.Hoffmann-La Roche Ag Nueva formulacion de dosificacion.
SI2774925T1 (sl) 2005-11-08 2017-04-26 Vertex Pharmaceuticals Incorporated Heterociklični modulatorji prenaơalcev z ATP-vezavno kaseto
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7872022B2 (en) * 2006-04-03 2011-01-18 Hoffmann-La Roche Inc. Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
HUE027630T2 (en) 2006-04-07 2016-10-28 Vertex Pharma Modulators of ATP-binding cassette transporters
US7754739B2 (en) * 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
WO2008141119A2 (en) 2007-05-09 2008-11-20 Vertex Pharmaceuticals Incorporated Modulators of cftr
PL2639222T3 (pl) * 2007-12-07 2017-02-28 Vertex Pharmaceuticals Incorporated SposĂłb wytwarzania kwasĂłw cykloalkilokarboksyamidopirydynobenzoesowych
CN103626744B (zh) 2007-12-07 2016-05-11 æČƒæł°ć…‹æ–ŻèŻç‰©è‚Ąä»œæœ‰é™ć…Źćž 3-(6-(1-(2,2-äșŒæ°Ÿè‹Żćč¶[d][1,3]问äșŒæ°§æ‚çŽŻæˆŠçƒŻ-5-ćŸș)çŽŻäž™çƒ·ç”Čé…°æ°šćŸș)-3-ç”ČćŸș搥敶-2-ćŸș)è‹Żç”Č酾的ć›șäœ“ćœąćŒ
US20100317663A1 (en) * 2008-02-19 2010-12-16 Jerry Leroy Adams Anilinopyridines as inhibitors of fak
EP2271622B1 (en) 2008-02-28 2017-10-04 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as CFTR Modulators
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
GB0814340D0 (en) 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
WO2011023733A1 (en) * 2009-08-27 2011-03-03 Glaxosmithkline Llc Anhydrate forms of a pyridine derivative
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
BR112012011485B1 (pt) 2009-11-18 2021-06-29 Helsinn Healthcare Sa Forma de dosagem e cĂĄpsula para tratar nĂĄusea e vĂŽmito
TW201143768A (en) * 2009-12-15 2011-12-16 Lundbeck & Co As H Pyridone derivatives as NK3 antagonists
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
HRP20160682T1 (hr) 2010-04-07 2016-07-29 Vertex Pharmaceuticals Incorporated Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksiamido)-3-metilpiridin-2-il)benzojeve kiseline
EP4005559B1 (en) 2010-04-07 2025-02-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
MX353408B (es) 2010-04-22 2018-01-11 Vertex Pharma Proceso para producir compuestos de cicloalquilcarboxamido-indol.
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
EP2560488B1 (en) * 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
EP2736329A4 (en) * 2011-07-29 2015-03-25 Tempero Pharmaceuticals Inc COMPOUNDS AND METHODS
US20140256740A1 (en) * 2011-07-29 2014-09-11 Tempero Pharmaceuticals, Inc. Compounds and methods
CN103889423B (zh) 2011-10-18 2016-10-19 è”«ć°”èŸ›ćŒ»ç–—è‚Ąä»œć…Źćž 愈抄ćŒčćŠć’Œćž•æŽ›èŻșćžçŒçš„æČ»ç–—æ€§ç»„ćˆ
US9254291B2 (en) 2011-11-08 2016-02-09 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
WO2014014841A1 (en) 2012-07-16 2014-01-23 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
WO2015068744A1 (ja) * 2013-11-08 2015-05-14 ă‚­ăƒƒă‚»ă‚€è–Źć“ć·„æ„­æ ȘćŒäŒšç€Ÿ ă‚«ăƒ«ăƒœă‚­ă‚·ăƒĄăƒăƒ«ăƒ”ăƒšăƒȘゾンèȘ˜ć°Žäœ“
CN105848657B (zh) 2013-11-12 2020-05-22 æČƒæł°ć…‹æ–ŻèŻç‰©è‚Ąä»œæœ‰é™ć…Źćž ćˆ¶ć€‡ç”šäșŽæȻ疗cfträ»‹ćŻŒçš„ç–Ÿç—…çš„èŻç‰©ç»„ćˆç‰©çš„æ–čæł•
PL3925607T3 (pl) 2014-04-15 2023-10-30 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorób, w których poƛredniczy mukowiscydozowy przezbƂonowy regulator przewodnictwa
EP3140007A1 (en) * 2014-05-05 2017-03-15 Apicore US LLC Methods of making netupitant and intermediates thereof
TWI649307B (zh) * 2014-05-07 2019-02-01 æ—„ć•†æ©˜ç”Ÿè—„ć“ć·„æ„­è‚Ąä»œæœ‰é™ć…Źćž Cyclohexylpyridine derivative
TW201613888A (en) 2014-09-26 2016-04-16 Helsinn Healthcare Sa Crystalline forms of an NK-1 antagonist
RS62259B1 (sr) 2014-11-18 2021-09-30 Vertex Pharma Proces izvođenja ispitivanja visoke propusnosti tečne hromatografije visokih performansi
EP3730140A1 (en) 2015-03-04 2020-10-28 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
CN105061303A (zh) * 2015-08-03 2015-11-18 æˆéƒœæŹŁæ·é«˜æ–°æŠ€æœŻćŒ€ć‘æœ‰é™ć…Źćž äž€ç§ćˆ¶ć€‡ć„ˆćŠ„ćĄćŠć…łé”źäž­é—Žäœ“n-ç”ČćŸș-4-(2-ç”ČćŸșè‹ŻćŸș)-6-(4-ç”ČćŸș-1-擌ć—ȘćŸș)-3-搥敶èƒș的新æ–čæł•
CA2996717A1 (en) 2015-09-11 2017-03-16 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
KR20180090302A (ko) 2015-12-07 2018-08-10 êčƒì„žìŽ ì•Œìż ížŒ êł ê” 가부시킀가읎샀 Nk1 수용ìČŽ êžží•­ì œ
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
TW202246215A (zh) * 2015-12-18 2022-12-01 çŸŽć•†äșžćŸ·ćˆ©ć…‹æ–Żć…Źćž 䜜ç‚ș非慹èș«ïœ”ïœ‡ïœ’ïŒ•äżƒæ•ˆćŠ‘äč‹ç¶“ć–ä»Łäč‹ïŒ”ïŒè‹ŻćŸșćĄć•¶ćŒ–ćˆç‰©
CN106892864A (zh) * 2015-12-21 2017-06-27 äžŠæ”·ç§‘èƒœèŻç‰©ç ”ć‘æœ‰é™ć…Źćž äž€ç§ć„ˆćŠ„çšźćŠæžžçŠ»çą±çš„æ™¶ćž‹aćŠć…¶ćˆ¶ć€‡æ–čæł•
EA201891472A1 (ru) * 2015-12-22 2018-12-28 йаĐșДЎа Đ€Đ°Ń€ĐŒĐ°ŃŃŒŃŽŃ‚ĐžĐșĐ°Đ» ĐšĐŸĐŒĐżĐ°ĐœĐž Đ›ĐžĐŒĐžŃ‚Đ”ĐŽ ĐąŃ€ĐŸĐčĐœŃ‹Đ” ĐŒĐŸĐŽŃƒĐ»ŃŃ‚ĐŸŃ€Ń‹ ŃĐœĐŽĐŸŃĐŸĐŒĐ°Đ»ŃŒĐœŃ‹Ń… Ń€Đ”Ń†Đ”ĐżŃ‚ĐŸŃ€ĐŸĐČ, ŃĐŸĐżŃ€ŃĐ¶Đ”ĐœĐœŃ‹Ń… с g-бДлĐșĐŸĐŒ
IL312486B2 (en) 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
KR20250069704A (ko) 2017-06-30 2025-05-19 ìČŽìŽìŠ€ 테띌퓚틱슀 ìœ”íŹë ˆìŽì…˜ 우욞슝을 ìč˜ëŁŒí•˜êž° 위한 nk-1 êžží•­ì œ ìĄ°ì„±ëŹŒ 및 우욞슝 ìč˜ëŁŒì— ì‚Źìš©í•˜ëŠ” ë°©ëȕ
CN109384712B (zh) * 2017-08-14 2021-05-07 挗äșŹćźœćŽšćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž é¶ć‘nk1ć—äœ“æ‹źæŠ—ć‰‚ćŠć…¶ćœšćŒ–ç–—æ‰€è‡Žæ¶ćżƒă€ć‘•ćæȻ疗䞭的ćș”甚
WO2019038656A1 (en) 2017-08-21 2019-02-28 Leiutis Pharmaceuticals Pvt, Ltd NEW TRIPLE COMBINATION FORMULATIONS FOR ANTIEMETIC THERAPY
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
FI3856338T3 (fi) * 2018-09-28 2025-02-03 Vanda Pharmaceuticals Inc Tradipitantin kÀyttö matkapahoinvoinnissa
WO2020132716A1 (en) * 2018-12-24 2020-07-02 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Chemical compound manufacture, new salt form, and therapeutic uses thereof
CN112174881B (zh) * 2019-07-04 2022-06-21 äžŠæ”·æŁźèŸ‰ćŒ»èŻæœ‰é™ć…Źćž äž€ç§ć„ˆćŠ„ćŒčćŠçš„èĄç”Ÿç‰©ćŠć…¶ćˆ¶ć€‡æ–čæł•
KR20220050956A (ko) * 2019-08-23 2022-04-25 ìœ ìŠ€íŠžëž„ëŠŹìŠ€ 파마슈티ìčŒìŠ€ 멬믾티드 (튞레읎딩 애슈 프레슀수띌 뉮로) ìč˜ëŁŒ ë°©ëȕ 및 읎의 용도
US20230190740A1 (en) 2020-04-03 2023-06-22 Nerre Therapeutics Limited An nk-1 receptor antagonist for treating a disease selecting from sepsis, septic shock, acute respiratory distress syndrome (ards) or multiple organ dysfunction syndrome (mods)
JP2023531863A (ja) 2020-06-02 2023-07-26 ネッレ ă‚»ăƒ©ăƒ”ăƒ„ăƒŒăƒ†ă‚Łă‚Żă‚č ăƒȘミテッド è‚șăźæ©Ÿæą°çš„æć‚·ă«ă‚ˆăŁăŠäżƒé€Čされるè‚șç·šç¶­ç—‡çŠ¶æ…‹ăźæČ»ç™‚ă§äœżç”šă™ă‚‹ăŸă‚ăźăƒ‹ăƒ„ăƒŒăƒ­ă‚­ăƒ‹ăƒłïŒˆïœŽïœ‹ïŒ‰ïŒïŒ‘ć—ćźčäœ“æ‹źæŠ—è–Ź
US12097197B2 (en) 2021-12-21 2024-09-24 Slayback Pharma Llc Stable liquid compositions of netupitant and palonosetron
EP4385500A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Fixed dose combination comprising netupitant and palonosetron
AU2023393578A1 (en) 2022-12-12 2025-07-03 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Fixed dose combination comprising netupitant and palonosetron
EP4385497A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron
WO2024126408A1 (en) 2022-12-12 2024-06-20 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Antioxidant-free fixed dose combination of netupitant and palonosetron

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1557420A (en) 1977-03-10 1979-12-12 Soc D Etudes Prod Chimique Preparation of isobutyramide derivatives
KR810001320B1 (ko) 1977-03-17 1981-10-14 삐에넎 위람 신규한 ìŽì†Œë¶€í‹°ëŒëŻžë“œë„˜ì˜ ì œìĄ°ë°©ëȕ
KR810001697B1 (ko) 1978-02-06 1981-10-27 삐에넎 위람 ìŽì†Œë¶€í‹°ëŒëŻžë“œ 유도ìČŽì˜ 신규한 ì œìĄ°ë°©ëȕ
EP0089765A3 (en) 1982-03-17 1984-05-23 Smith Kline & French Laboratories Limited Pyridine derivatives
US4745123A (en) * 1986-02-18 1988-05-17 Warner-Lambert Company Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents
GB8607312D0 (en) 1986-03-25 1986-04-30 Ici Plc Therapeutic agents
GB8607313D0 (en) 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
CA1339423C (en) 1988-09-14 1997-09-02 Yuji Ono Pyridine compounds and pharmaceutical use thereof
US4994456A (en) 1989-03-01 1991-02-19 Nisshin Flour Milling Co., Ltd. Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same
US4973597A (en) 1989-06-30 1990-11-27 Eli Lilly And Company Anticonvulsant agents
HU207047B (en) 1989-11-07 1993-03-01 Richter Gedeon Vegyeszet Process for producing new pyridine derivatives and pharmaceutical copositions comprising same
US5364943A (en) 1991-11-27 1994-11-15 Pfizer Inc. Preparation of substituted piperidines
GB9021056D0 (en) 1990-09-27 1990-11-07 Pfizer Ltd Antiarrhythmic agents
GB9214120D0 (en) 1991-07-25 1992-08-12 Ici Plc Therapeutic amides
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
AU4718093A (en) 1992-07-31 1994-03-03 Merck Sharp & Dohme Limited Substituted amines as tachykinin receptor antagonists
US5387595A (en) 1992-08-26 1995-02-07 Merck & Co., Inc. Alicyclic compounds as tachykinin receptor antagonists
GB9305672D0 (en) 1993-03-19 1993-05-05 Wyeth John & Brother Ltd Amide derivatives
NZ264063A (en) 1993-08-13 1995-11-27 Nihon Nohyaku Co Ltd N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
DE69434063D1 (de) 1993-12-29 2004-11-11 Merck Sharp & Dohme Substituierte Morpholinderivate und ihre Verwendung als therapeutische Mittel
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
JPH10501228A (ja) 1994-06-06 1998-02-03 ăƒŻăƒŒăƒŠăƒŒâˆ’ăƒ©ăƒłăƒăƒŒăƒˆăƒ»ă‚łăƒłăƒ‘ăƒ‹ăƒŒ ă‚żă‚­ă‚­ăƒ‹ăƒłïŒˆïœŽïœ‹â–Čäž‹ïŒ‘â–ŒïŒ‰ć—ćźčäœ“ă‚ąăƒłă‚żă‚Žăƒ‹ă‚čト
US6294537B1 (en) 1995-03-17 2001-09-25 Sanofi-Synthelabo Compounds which are specific antagonists of the human NK3 receptor and their use as medicinal products and diagnostic tools
ATE242243T1 (de) * 1995-03-24 2003-06-15 Takeda Chemical Industries Ltd Zyklische verbindungen, ihre herstellung und ihre verwendung als tachykininrezeptorantagonisten
AR004735A1 (es) * 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
KR100313641B1 (ko) 1996-03-29 2002-02-19 디. 제읎. 우드, 슀플êȔ 알렌 제읎 6-íŽ˜ë‹í”ŒëŠŹë”œ-2-ì•„ëŻŒìœ ë„ìČŽ
AU4885097A (en) 1996-11-08 1998-06-03 Sankyo Company Limited Arylureas or arylmethylcarbamoyl derivatives
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
RU2238264C2 (ru) * 1999-02-24 2004-10-20 Đ€.Đ„ĐŸŃ„Ń„ĐŒĐ°ĐœĐœ-Ля Đ ĐŸŃˆ Аг ĐŸŃ€ĐŸĐžĐ·ĐČĐŸĐŽĐœŃ‹Đ” Đ±Đ”ĐœĐ·ĐŸĐ»Đ° ОлО ĐżĐžŃ€ĐžĐŽĐžĐœĐ° Đž Ń„Đ°Ń€ĐŒĐ°Ń†Đ”ĐČтОчДсĐșая ĐșĐŸĐŒĐżĐŸĐ·ĐžŃ†ĐžŃ ĐœĐ° ох ĐŸŃĐœĐŸĐČĐ”
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
ATE253561T1 (de) * 1999-11-29 2003-11-15 Hoffmann La Roche 2-(3,5-bis-trifluoromethyl-phenyl)-n-methyl-n-( - morpholin-4-yl-4-o-tolyl-pyridin-3-yl)- isobutyramid

Also Published As

Publication number Publication date
HU0000748D0 (en) 2000-04-28
IT1320763B1 (it) 2003-12-10
GB2347422A (en) 2000-09-06
RS20080562A (en) 2009-09-08
US6297375B1 (en) 2001-10-02
DK1035115T3 (da) 2005-01-24
SK287911B6 (sk) 2012-03-02
PT1035115E (pt) 2005-01-31
EP1394150B1 (en) 2011-01-19
NO20000885L (no) 2000-08-25
TR200000520A2 (tr) 2001-06-21
CY1111317T1 (el) 2015-08-05
BE2015C057I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2019-03-06
HRP20080306B1 (hr) 2015-01-30
AR062949A2 (es) 2008-12-17
NZ502948A (en) 2001-09-28
HK1031223A1 (en) 2001-06-08
SK287912B6 (sk) 2012-03-02
EA200000155A2 (ru) 2000-08-28
NO20000885D0 (no) 2000-02-23
DE10008042A1 (de) 2000-08-31
NL300758I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-12-22
MY123648A (en) 2006-05-31
GEP20022676B (en) 2002-04-25
AR029614A1 (es) 2003-07-10
CA2299139A1 (en) 2000-08-24
BG104187A (en) 2000-11-30
EP1394150A1 (en) 2004-03-03
PA8491101A1 (es) 2001-04-30
FR15C0049I1 (fr) 2015-08-28
BR0000908B1 (pt) 2013-09-24
JO2294B1 (en) 2005-09-12
HRP20000097A2 (en) 2001-10-31
SE1035115T3 (sv) 2005-01-18
TNSN00032A1 (fr) 2005-11-10
KR20000062599A (ko) 2000-10-25
EP1035115A1 (en) 2000-09-13
MA26722A1 (fr) 2004-12-20
CY2015042I1 (el) 2016-06-22
AU1946800A (en) 2000-08-31
LTPA2015036I1 (lt) 2015-11-25
RS53869B1 (en) 2015-08-31
EP1035115B1 (en) 2004-09-29
DK1394150T3 (da) 2011-03-21
ME00593B (me) 2015-08-31
FR2790473B1 (fr) 2004-04-02
OA11680A (fr) 2005-01-12
PL338598A1 (en) 2000-08-28
KR100384904B1 (ko) 2003-05-22
EA200000155A3 (ru) 2000-12-25
BR0000908A (pt) 2000-09-12
FR15C0049I2 (fr) 2016-02-12
PL217311B1 (pl) 2014-07-31
SI1035115T1 (en) 2005-02-28
RS50194B (sr) 2009-05-06
US20020091265A1 (en) 2002-07-11
CZ2000609A3 (cs) 2001-01-17
PT1394150E (pt) 2011-02-17
ZA200000894B (en) 2000-08-24
CY2015041I1 (el) 2016-06-22
ATE496032T1 (de) 2011-02-15
NO315554B1 (no) 2003-09-22
HRP20000097B1 (en) 2008-12-31
EG23817A (en) 2007-09-19
SE1035115T5 (sv) 2015-08-04
DE60045564D1 (de) 2011-03-03
ITMI20000328A1 (it) 2001-08-23
LTC1035115I2 (lt) 2017-04-10
IL134654A (en) 2011-03-31
HUP0000748A2 (en) 2001-03-28
NL300758I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-12-22
CN1142144C (zh) 2004-03-17
ITMI20000328A0 (it) 2000-02-23
SG91856A1 (en) 2002-10-15
UY32314A (es) 2010-02-26
ES2359235T3 (es) 2011-05-19
MEP5709A (en) 2011-12-20
FR2790473A1 (fr) 2000-09-08
JP2000247957A (ja) 2000-09-12
ATE277905T1 (de) 2004-10-15
IS2116B (is) 2006-06-15
HU227629B1 (en) 2011-10-28
DE60014216D1 (de) 2004-11-04
CA2299139C (en) 2011-03-29
TR200000520A3 (tr) 2001-06-21
ES2171109A1 (es) 2002-08-16
EA003673B1 (ru) 2003-08-28
BRPI0000908B8 (pt) 2021-05-25
TWI288746B (en) 2007-10-21
AU767048B2 (en) 2003-10-30
CZ300596B6 (cs) 2009-06-24
BG64554B1 (bg) 2005-07-29
JP3399900B2 (ja) 2003-04-21
YU9500A (sh) 2002-11-15
HUP0000748A3 (en) 2003-12-29
LU92745I2 (fr) 2015-08-17
IS5381A (is) 2000-08-25
SV2002000024A (es) 2002-01-23
DE60014216T2 (de) 2006-03-02
MY147451A (en) 2012-12-14
ES2171109B2 (es) 2003-09-16
SK2352000A3 (en) 2000-09-12
ES2226622T3 (es) 2005-04-01
GT200000017A (es) 2001-08-15
GB0003908D0 (en) 2000-04-05
CY2015041I2 (el) 2016-06-22
HRP20080306A2 (en) 2008-11-30
US6479483B2 (en) 2002-11-12
CN1270959A (zh) 2000-10-25
IL134654A0 (en) 2001-04-30
UA71547C2 (uk) 2004-12-15

Similar Documents

Publication Publication Date Title
PE20001467A1 (es) Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina
PE20010009A1 (es) Derivados de fenil - y piridinilo como antagonistas del receptor de la neuroquinina 1
PE20050482A1 (es) Derivados de dihidrobenzofuranilo alcanamida
PE20020258A1 (es) Derivados de 4-fenil-piridina como antagonistas del receptor de neuroquinina 1 (nk-1)
PE20030238A1 (es) Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales y neuronales
PE20000325A1 (es) Derivados de 2-ariletil-(piperidin-4-ilmetil)amina
ATE139233T1 (de) Annelierte thiophen-derivate, ihre herstellung und verwendung
PE20020721A1 (es) Derivados de quinuclidina como agentes antimuscarinicos m3
UY27029A1 (es) Nuevos derivados de pirazolpiridina sustituidos con piridina
PE20001551A1 (es) Derivados de eter biarilico como inhibidores de la recaptacion de monoaminas para el tratamiento de trastornos del snc
BR0306208A (pt) Compostos de dibenzilamina e seu uso farmacĂȘutico
PE20010741A1 (es) Derivados de piperazina como antagonistas de taquicininas
PE106499A1 (es) Antagonistas del receptor ccr-3
AR029616A1 (es) Compuestos derivados de 3-fenil-piridina, su uso, un proceso para prepararlos y medicamentos que los contienen
PE20000170A1 (es) Derivados benzosulfonas
PE20020657A1 (es) Derivados de amida de piperidinas 1,4-disustituidas de formula (i)
PE20021072A1 (es) DERIVADOS DE DIHIDRO-BENZO(b) (1,4)-DIAZEPIN-2-ONA COMO ANTAGONISTAS I DE mGLUR2
ES2113081T3 (es) 1,4-benzotiazepinas utiles como agentes neurologicos.
PE20011114A1 (es) Decahidro-isoquinolinas
PE20040772A1 (es) Composicion y actividad antiviral de derivados de piperazina azaindoloxoaceticos
ATE377602T1 (de) Morphinanderivate und ihre medizinische anwendung
PE20030761A1 (es) Derivados del 7-amino-benzotiazol
PE20040757A1 (es) Derivados de benzoxazina
ES2154605B1 (es) Nuevos derivados mixtos de bencimidazol-arilpiperazina con afinidad por los receptores serotoninergicos 5-ht1a y 5-ht3
JO2235B1 (en) Derivatives of phenyl

Legal Events

Date Code Title Description
FG Grant, registration
MK Expiration of term